Next Article in Journal
Evaluation of a Methylcellulose and Hyaluronic Acid Hydrogel as a Vehicle for Rectal Delivery of Biologics
Next Article in Special Issue
DPYD and Fluorouracil-Based Chemotherapy: Mini Review and Case Report
Previous Article in Journal
Spatially Specific Liposomal Cancer Therapy Triggered by Clinical External Sources of Energy
Communication

Impact of Polypharmacy on Candidate Biomarker miRNomes for the Diagnosis of Fibromyalgia and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Striking Back on Treatments

1
Escuela de Doctorado, Universidad Católica de Valencia San Vicente Mártir, 46001 Valencia, Spain
2
School of Medicine, Universidad Católica de Valencia San Vicente Mártir, 46001 Valencia, Spain
3
Kiran C Patel College of Osteopathic Medicine, Nova Southeastern University, Ft Lauderdale, FL 33314, USA
4
Institute for Neuro Immune Medicine, Nova Southeastern University, Ft Lauderdale, FL 33314, USA
5
Unidad Mixta CIPF-UCV, Centro de Investigación Príncipe Felipe, 46012 Valencia, Spain
*
Author to whom correspondence should be addressed.
Pharmaceutics 2019, 11(3), 126; https://doi.org/10.3390/pharmaceutics11030126
Received: 15 January 2019 / Revised: 26 February 2019 / Accepted: 5 March 2019 / Published: 18 March 2019
Fibromyalgia (FM) and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) are diseases of unknown etiology presenting complex and often overlapping symptomatology. Despite promising advances on the study of miRNomes of these diseases, no validated molecular diagnostic biomarker yet exists. Since FM and ME/CFS patient treatments commonly include polypharmacy, it is of concern that biomarker miRNAs are masked by drug interactions. Aiming at discriminating between drug-effects and true disease-associated differential miRNA expression, we evaluated the potential impact of commonly prescribed drugs on disease miRNomes, as reported by the literature. By using the web search tools SM2miR, Pharmaco-miR, and repoDB, we found a list of commonly prescribed drugs that impact FM and ME/CFS miRNomes and therefore could be interfering in the process of biomarker discovery. On another end, disease-associated miRNomes may incline a patient’s response to treatment and toxicity. Here, we explored treatments for diseases in general that could be affected by FM and ME/CFS miRNomes, finding a long list of them, including treatments for lymphoma, a type of cancer affecting ME/CFS patients at a higher rate than healthy population. We conclude that FM and ME/CFS miRNomes could help refine pharmacogenomic/pharmacoepigenomic analysis to elevate future personalized medicine and precision medicine programs in the clinic. View Full-Text
Keywords: fibromyalgia (FM); myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS); microRNA; miRNome; pharmacogenomics; pharmacoepigenomics; SM2miR; Pharmaco-miR; repoDB; ME/CFS Common Data Elements (CDEs) fibromyalgia (FM); myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS); microRNA; miRNome; pharmacogenomics; pharmacoepigenomics; SM2miR; Pharmaco-miR; repoDB; ME/CFS Common Data Elements (CDEs)
MDPI and ACS Style

Almenar-Pérez, E.; Sánchez-Fito, T.; Ovejero, T.; Nathanson, L.; Oltra, E. Impact of Polypharmacy on Candidate Biomarker miRNomes for the Diagnosis of Fibromyalgia and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Striking Back on Treatments. Pharmaceutics 2019, 11, 126. https://doi.org/10.3390/pharmaceutics11030126

AMA Style

Almenar-Pérez E, Sánchez-Fito T, Ovejero T, Nathanson L, Oltra E. Impact of Polypharmacy on Candidate Biomarker miRNomes for the Diagnosis of Fibromyalgia and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Striking Back on Treatments. Pharmaceutics. 2019; 11(3):126. https://doi.org/10.3390/pharmaceutics11030126

Chicago/Turabian Style

Almenar-Pérez, Eloy, Teresa Sánchez-Fito, Tamara Ovejero, Lubov Nathanson, and Elisa Oltra. 2019. "Impact of Polypharmacy on Candidate Biomarker miRNomes for the Diagnosis of Fibromyalgia and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Striking Back on Treatments" Pharmaceutics 11, no. 3: 126. https://doi.org/10.3390/pharmaceutics11030126

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop